(0)
San Francisco, California (Newsfile Corp. - April 13, 2021) - Cofactor Genomics, the company bridging the precision medicine gap, today announced commencement of the first multicenter clinical trial of its OncoPrismTM diagnostic assay, using the company s patented approach to generating multidimensional immune biomarkers. Fifteen hospitals and healthcare networks, including Mayo Clinic, MultiCare Institute for Research and Innovation, and Revive Research Institute, are currently enrolling in the PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) Trial to evaluate use of the OncoPrism test in patients with recurrent and metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) to effectively predict a patient s response to immunotherapy. The company expects additional sites to join the trial before the end of 2021.
Q&A: A MultiCare doctor answers your questions about the Novavax COVID-19 vaccine trial
How much you could get paid, whether or not you ll be a candidate for another vaccine and more of your questions answered here. Author: KREM Staff Updated: 7:19 PM MST January 8, 2021
CHENEY, Wash. MultiCare Health System is bringing a Phase 3 clinical trial of the Novavax COVID-19 vaccine to the Inland Northwest.
The hospital system is looking for 300 people to volunteer.
Dr. Jonathan Staben with MultiCare joined Up with KREM to answer viewers questions about the vaccine, and what participating in the trial would entail.
Dr. Jonathan Staben is a board-certified Family Physician with MultiCare Health System in the Inland Northwest. He has been involved in clinical research since 2007 and has acted as a principal investigator on a number of vaccine trials. Dr. Staben, along with the Multicare Institute for Research and Innovation, will be particip